Ascend Laboratories recalled Atorvastatin Calcium Tablets, 80 mg, on September 19, 2025. The recall affects 90-count and 500-count bottles due to failed dissolution specifications. Consumers should stop using the product immediately and consult their healthcare provider.
Failed Dissolution Specifications
Consumers and healthcare providers should stop using this product immediately. Contact Ascend Laboratories, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled products include Atorvastatin Calcium Tablets USP, 80 mg, with NDC numbers 67877-514-90 (90-count) and 67877-514-05 (500-count). They were manufactured by Alkem Laboratories in India and distributed by Ascend Laboratories, LLC, in Parsippany, NJ.
The recall stems from failed dissolution specifications, which may affect the effectiveness of the medication. Atorvastatin is commonly used to lower cholesterol and reduce the risk of heart disease.
No specific incidents of injury or adverse effects have been reported in connection with this recall. The failure in dissolution could potentially lead to ineffective treatment.
Consumers and healthcare providers should stop using Atorvastatin Calcium Tablets immediately. Contact Ascend Laboratories, LLC, or your healthcare provider for further guidance on the recall.
For more information, contact Ascend Laboratories at 1-800-XXX-XXXX or visit their website. Additional details can be found at the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.